Advertisement

Journal of Neurology

, Volume 255, Issue 11, pp 1721–1725 | Cite as

Levetiracetam in stiff-person syndrome

  • GianPietro Sechi
  • Marianna Barrocu
  • Maria G. Piluzza
  • Giovanni A. Cocco
  • Giovanni A. Deiana
  • Gian Franco Sau
ORIGINAL COMMUNICATION

Abstract

We studied the effects of oral levetiracetam (LEV) (500 mg twice daily) in three women with stiff-person syndrome in a single-blind, placebo-controlled study. The severity of muscle rigidity and of paroxysmal symptoms was assessed by EMG and clinically by a rating scale of 0–4 and by the Patients Global Impressions Scale. LEV was well tolerated. On active treatment all patients improved as assessed by any of the objective or subjective outcome measures. No response was noticed on placebo. Our data indicate that in patients with SPS, LEV is well tolerated and has a therapeutic role in the management of both muscle stiffness and life-threatening paroxysmal respiratory spasms.

Key words

stiff-person syndrome levetiracetam clinical trial 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dalakas MC, Fujii M, Li M, McElroy B (2000) The clinical spectrum of anti- GAD antibody-positive patients with stiff-person syndrome. Neurology 55:1531–1535PubMedGoogle Scholar
  2. 2.
    Guy W (1976) (Ed) ECDEV assessment manual for psychopharmacology. Revised ed. Bethesda, MD: U.S. Department of Health, Education and WelfareGoogle Scholar
  3. 3.
    Levy LM, Dalakas MC, Floeter MK (1999) The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of γ-aminobutyric acid. Ann Intern Med 131:522–530PubMedGoogle Scholar
  4. 4.
    Lynch BA, Lambeng N, Nocka K, et al. (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 10:19861−19866Google Scholar
  5. 5.
    Palma E, Ragozzino D, Angelantonio SD, et al. (2007) The antiepileptic drug levetiracetam stabilizes the human epileptic GABA (A) receptors upon repetitive activation. Epilepsia 48:1842–1849PubMedCrossRefGoogle Scholar
  6. 6.
    Pisani A, Bonsi P, Martella G, et al. (2004) Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine. Epilepsia 45:719−728PubMedCrossRefGoogle Scholar
  7. 7.
    Ptsalos PN (2000) Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 85:77–85CrossRefGoogle Scholar
  8. 8.
    Raju R, Rakocevic G, Chen Z, et al. (2006) Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain 129:3270–3276PubMedCrossRefGoogle Scholar
  9. 9.
    Rigo JM, Hans G, Nguyen L, et al. (2002) The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 13:6659−6672Google Scholar
  10. 10.
    Rüegg SJ, Steck AJ, Fuhr P (2004) Levetiracetam improves paroxysmal symptoms in a patient with stiff-person syndrome. Neurology 62:338PubMedGoogle Scholar
  11. 11.
    Ueda Y, Doi T, Nagatomo K, et al. (2007) Effect of levetiracetam on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl3 injection. Brain Research 1151:55 – 61PubMedCrossRefGoogle Scholar
  12. 12.
    Vasconcelos O, Dalakas MC (2003) Stiff-person syndrome. Curr Treat Options Neurol 5:79–90PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • GianPietro Sechi
    • 1
  • Marianna Barrocu
    • 1
  • Maria G. Piluzza
    • 1
  • Giovanni A. Cocco
    • 1
  • Giovanni A. Deiana
    • 1
  • Gian Franco Sau
    • 1
  1. 1.Dept. of NeurosciencesUniversity of SassariSassariItaly

Personalised recommendations